Background: Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder characterized by metabolic dysregulation and impaired reproductive function. Insulin resistance is a central pathogenic mechanism contributing to hyperandrogenism and ovulatory dysfunction. Given the heterogeneity of PCOS, treatment strategies increasingly focus on individualized and combined therapeutic approaches.

Objective: To evaluate the effects of personalized and combined treatment strategies, including lifestyle interventions and pharmacological therapy, on insulin resistance and reproductive function in women with polycystic ovary syndrome.

Methods: A prospective analytical study was conducted involving women of reproductive age diagnosed with PCOS according to the Rotterdam criteria. Participants received either lifestyle intervention alone or a combination of lifestyle modification and individualized pharmacological therapy. Insulin sensitivity was assessed using fasting insulin levels and the HOMA-IR index. Reproductive outcomes were evaluated by menstrual cycle characteristics, ovulatory function, and endocrine parameters before and after treatment.

Results: Patients receiving combined therapy demonstrated a more pronounced improvement in insulin sensitivity, reflected by a significant decrease in fasting insulin levels and HOMA-IR values. Restoration of regular menstrual cycles and ovulation occurred more frequently in the combined treatment group. Individualized therapeutic regimens were associated with improved hormonal balance and a reduction in clinical manifestations of hyperandrogenism.

Conclusion: Personalized and combined therapeutic strategies provide superior metabolic and reproductive benefits in women with PCOS compared to lifestyle intervention alone. These findings support the implementation of individualized treatment algorithms targeting both insulin resistance and reproductive dysfunction.

Polycystic ovary syndrome; individualized therapy; insulin resistance; lifestyle intervention; reproductive function.

Bozdag G. et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.

ESHRE Guideline Group on PCOS. International evidence-based guideline for the assessment and management of PCOS. Hum Reprod. 2023;38(4):579–602.

Patten R. et al. MRI in polycystic ovary syndrome: diagnostic advances and clinical value. Clin Radiol. 2018;73(5):410–417.

Farquhar C. et al. Laparoscopic drilling for ovulation induction in clomiphene-resistant PCOS. Cochrane Database Syst Rev. 2012;(6):CD001122.

Amer S.A. et al. Long-term outcome of laparoscopic ovarian drilling in PCOS. Hum Reprod. 2017;32(6):1171–1179.

Li C. et al. Low-energy laparoscopic ovarian drilling reduces adhesion risk. Reprod Biol Endocrinol. 2020;18(1):1–9.

Sfakianoudis K. et al. Ovarian rejuvenation with PRP in reproductive-age women. Front Endocrinol. 2019;10:806.

Ding L. et al. Mesenchymal stem cells restore ovarian function through anti-inflammatory mechanisms. Stem Cell Res Ther. 2019;10(1):1–13.

Walls M.L., Hart R. In vitro maturation for fertility preservation. Reprod Fertil Dev. 2018;30(10):1437–1445.

Singh N. et al. Role of hysteroscopy and endometrial interventions in improving IVF outcomes. J Hum Reprod Sci. 2021;14(3):189–198.